Archive · 21 Jul 2026
India Approves First Dengue Vaccine Qdenga
India has approved its first vaccine for dengue, called Qdenga.
This vaccine is made by a company in Germany and is designed to protect people from all four types of dengue virus.
It is given as two injections, three months apart, and is approved for people aged 4 to 60 years.
The vaccine has been tested in many countries and has been shown to be safe and effective.
Over 24 million doses have been given worldwide.
The Indian government says this vaccine will help in fighting dengue, but people should still take other steps to prevent the disease, like getting rid of mosquito breeding sites.
India has approved its first dengue vaccine, Qdenga, developed by Takeda GmbH, Germany.
The vaccine is a live, attenuated tetravalent vaccine designed to protect against all four dengue virus serotypes.
Qdenga is approved for people aged 4 to 60 years and is administered as two doses, three months apart.
The approval is backed by extensive global clinical trials and has been prequalified by the World Health Organization (WHO).
The vaccine is expected to complement existing dengue prevention measures, including vector control and personal protective measures.
- Who
- The Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare, India.
- What
- Approval of India's first dengue vaccine, Qdenga.
- When
- Tuesday (specific date not mentioned).
- Where
- India.
- Why
- To strengthen the country's response to dengue, one of its fastest-growing mosquito-borne diseases.
Vaccine Advocates
Prevention Focus Advocates
Role of Vaccination
Vaccine Advocates
Vaccination is a crucial step in controlling dengue and should be widely promoted.
Prevention Focus Advocates
Vaccination should complement, not replace, traditional prevention methods like vector control and personal protective measures.
- Vaccine Name
- Qdenga
- Developer
- Takeda GmbH, Germany
- Approval Authority
- Central Drugs Standard Control Organisation (CDSCO)
- Age Group Approved
- 4 to 60 years
- Doses Required
- Two doses of 0.5 ml each, three months apart
- Global Approvals
- 42 countries, including EU, UK, Switzerland, Indonesia, Malaysia, Thailand
- WHO Status
- Prequalified
- Global Doses Distributed
- More than 24 million